Company news
Corbus Pharmaceuticals Holdings, Inc. news in 2019
Corbus Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2019, newest first.
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
November 17, 2019
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
November 10, 2019
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
November 6, 2019
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
October 2, 2019
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
April 17, 2019
Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors
April 7, 2019
Decks in 2019
- Investor Presentation (November 2019)
Investor deck · 46 slides · Nov 25, 2019